80 related articles for article (PubMed ID: 25312087)
1. Lentiviral-based approach for the validation of cancer therapeutic targets in vivo.
Ambrogio C; Stern P; Scuoppo C; Kranz H; Barbacid M; Santamaría D
Biotechniques; 2014 Oct; 57(4):179, 181-7. PubMed ID: 25312087
[TBL] [Abstract][Full Text] [Related]
2. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
[TBL] [Abstract][Full Text] [Related]
3. Cancer cells as targets for lentivirus-mediated gene transfer and gene therapy.
Pellinen R; Hakkarainen T; Wahlfors T; Tulimäki K; Ketola A; Tenhunen A; Salonen T; Wahlfors J
Int J Oncol; 2004 Dec; 25(6):1753-62. PubMed ID: 15547714
[TBL] [Abstract][Full Text] [Related]
4. Transcriptional targeting of virus-mediated gene transfer by the human hexokinase II promoter.
Määttä AM; Korja S; Venhoranta H; Hakkarainen T; Pirinen E; Heikkinen S; Pellinen R; Mäkinen K; Wahlfors J
Int J Mol Med; 2006 Nov; 18(5):901-8. PubMed ID: 17016620
[TBL] [Abstract][Full Text] [Related]
5. Lentivirus-mediated carboxyl-terminal modulator protein gene transfection via aerosol in lungs of K-ras null mice.
Hwang SK; Kwon JT; Park SJ; Chang SH; Lee ES; Chung YS; Beck GR; Lee KH; Piao L; Park J; Cho MH
Gene Ther; 2007 Dec; 14(24):1721-30. PubMed ID: 17960162
[TBL] [Abstract][Full Text] [Related]
6. Novel cationic cardiolipin analogue-based liposome for efficient DNA and small interfering RNA delivery in vitro and in vivo.
Chien PY; Wang J; Carbonaro D; Lei S; Miller B; Sheikh S; Ali SM; Ahmad MU; Ahmad I
Cancer Gene Ther; 2005 Mar; 12(3):321-8. PubMed ID: 15578064
[TBL] [Abstract][Full Text] [Related]
7. Involvement of Ras/Raf-1/ERK actions in the magnolol-induced upregulation of p21 and cell-cycle arrest in colon cancer cells.
Hsu YF; Lee TS; Lin SY; Hsu SP; Juan SH; Hsu YH; Zhong WB; Lee WS
Mol Carcinog; 2007 Apr; 46(4):275-83. PubMed ID: 17295239
[TBL] [Abstract][Full Text] [Related]
8. Crosstalk between hedgehog and other signaling pathways as a basis for combination therapies in cancer.
Brechbiel J; Miller-Moslin K; Adjei AA
Cancer Treat Rev; 2014 Jul; 40(6):750-9. PubMed ID: 24613036
[TBL] [Abstract][Full Text] [Related]
9. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
[TBL] [Abstract][Full Text] [Related]
10. Non-primate lentiviral vectors.
Poeschla EM
Curr Opin Mol Ther; 2003 Oct; 5(5):529-40. PubMed ID: 14601523
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of lentivirus-mediated and MUC1 antibody-targeted VP22-TK/GCV suicide gene therapy for ovarian cancer.
Kong B; Wang W; Liu C; Song L; Ma D; Qu X; Jiang J; Yang X; Zhang Y; Wang B; Wei MQ; Yang Q
In Vivo; 2003; 17(2):153-6. PubMed ID: 12792977
[TBL] [Abstract][Full Text] [Related]
12. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
[TBL] [Abstract][Full Text] [Related]
13. Raf: a strategic target for therapeutic development against cancer.
Beeram M; Patnaik A; Rowinsky EK
J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA.
Zhang YA; Nemunaitis J; Samuel SK; Chen P; Shen Y; Tong AW
Cancer Res; 2006 Oct; 66(19):9736-43. PubMed ID: 17018633
[TBL] [Abstract][Full Text] [Related]
15. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.
Indraccolo S; Habeler W; Tisato V; Stievano L; Piovan E; Tosello V; Esposito G; Wagner R; Uberla K; Chieco-Bianchi L; Amadori A
Cancer Res; 2002 Nov; 62(21):6099-107. PubMed ID: 12414634
[TBL] [Abstract][Full Text] [Related]
16. Lentivirus-based DsRed-2-transfected pancreatic cancer cells for deep in vivo imaging of metastatic disease.
Zhou J; Yu Z; Zhao S; Hu L; Zheng J; Yang D; Bouvet M; Hoffman RM
J Surg Res; 2009 Nov; 157(1):63-70. PubMed ID: 19589544
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of physical RAF/14-3-3 interaction by cotylenin A as treatment strategy for RAS mutant cancers.
Molzan M; Kasper S; Röglin L; Skwarczynska M; Sassa T; Inoue T; Breitenbuecher F; Ohkanda J; Kato N; Schuler M; Ottmann C
ACS Chem Biol; 2013 Sep; 8(9):1869-75. PubMed ID: 23808890
[TBL] [Abstract][Full Text] [Related]
18. A quantitative and multiplexed approach to uncover the fitness landscape of tumor suppression in vivo.
Rogers ZN; McFarland CD; Winters IP; Naranjo S; Chuang CH; Petrov D; Winslow MM
Nat Methods; 2017 Jul; 14(7):737-742. PubMed ID: 28530655
[TBL] [Abstract][Full Text] [Related]
19. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
[TBL] [Abstract][Full Text] [Related]
20. A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.
Li W; Xie S; Guo X; Gong X; Wang S; Lin D; Zhang J; Ren Z; Huang S; Zeng F; Zeng Y
Haematologica; 2008 Mar; 93(3):356-62. PubMed ID: 18268280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
